Clinical Trials Directory

Trials / Completed

CompletedNCT01012141

Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer

Pilot Phase II Study of Docetaxel in Combination With a Dietary Phytonutrient in First Line Treatment of Hormone Independent Metastatic Prostate Cancer

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Centre Jean Perrin · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE : Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Dietary supplements, such as phytochemicals, may stop or delay the development of prostate cancer.

Detailed description

The purpose of this study is to assess the pathological response rate in metastatic prostate cancer patients treated by : Docetaxel with a phytochemical

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTphytochemical
DRUGDocetaxel

Timeline

Start date
2009-09-01
Primary completion
2011-04-01
Completion
2011-04-01
First posted
2009-11-11
Last updated
2013-04-10

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT01012141. Inclusion in this directory is not an endorsement.

Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer (NCT01012141) · Clinical Trials Directory